Jatenzo and Imaging Contrast Dye: What You Need to Know Before Your Scan

Does Jatenzo Directly Interact With Contrast Dye?

No direct pharmacokinetic or pharmacodynamic interaction between Jatenzo and either iodinated or gadolinium-based contrast media (GBCM) is documented in the FDA prescribing information or published clinical literature [1]. Testosterone undecanoate is absorbed via intestinal lymphatics, metabolized in the liver and peripheral tissues to testosterone and dihydrotestosterone, and excreted in urine and feces as glucuronide and sulfate conjugates [1]. Contrast agents are eliminated unchanged by glomerular filtration. The two drug classes share no metabolic enzymes, plasma transporters, or excretion pathways that would produce a classical drug-drug interaction.

Why Radiologists Still Need to Know

Even without a direct interaction, radiologists and technologists routinely ask about all medications before contrast injection. Testosterone therapy affects hematocrit, blood pressure, and renal perfusion, all variables that modify contrast-related risk [2]. The American College of Radiology (ACR) Manual on Contrast Media (v2023) states that "pre-existing renal insufficiency, diabetes mellitus, dehydration, and hemodynamic instability are the principal risk factors for contrast-induced acute kidney injury (CI-AKI)" [3]. Jatenzo does not cause renal insufficiency directly, but elevated hematocrit from polycythemia raises blood viscosity, which may reduce renal perfusion under contrast-induced osmotic stress.

Pharmacokinetic Summary

Jatenzo capsules must be taken with a meal containing at least 20 to 23 g of fat to achieve therapeutic absorption through the lymphatic route [1]. Peak testosterone concentrations (Cmax) occur roughly 4 to 6 hours post-dose. Testosterone binds extensively to sex hormone-binding globulin (SHBG) and albumin; neither iodinated contrast nor GBCM displaces testosterone from these proteins at clinically relevant concentrations, based on protein-binding studies of comparable molecular-weight compounds [4].

Hematocrit Elevation: The Real Contrast-Related Risk on Jatenzo

Polycythemia is the most clinically significant adverse effect of Jatenzo in the context of imaging. The FDA label requires hematocrit monitoring at baseline, at 3 to 4 months, and then annually [1]. In the key JATENZO phase-3 trial (N=166), 24% of participants developed a hematocrit exceeding 54%, and the label mandates dose reduction or discontinuation if hematocrit reaches 54% [1].

How Elevated Hematocrit Affects Contrast Risk

Iodinated contrast agents are hyperosmolar or iso-osmolar solutions. When injected intravenously, they draw fluid into the vascular space and then pass rapidly into the renal tubules. Blood with a hematocrit above 52% has measurably higher viscosity, which prolongs transit time through the renal medullary vasculature and concentrates the contrast bolus in tubular cells longer than normal [5]. A retrospective analysis of 11,516 patients undergoing coronary angiography published in the American Journal of Cardiology found that baseline hematocrit above 52% was an independent predictor of contrast-induced nephropathy (odds ratio 1.44, P<0.01) [5].

Pre-Scan Hematocrit Check

If you are on Jatenzo and scheduled for any contrast-enhanced CT, cardiac catheterization, or contrast fluoroscopy, request a complete blood count within 30 days of the procedure. An eGFR drawn at the same time satisfies the ACR pre-contrast renal screening recommendation for patients with risk factors [3]. If hematocrit exceeds 54%, notify both your prescribing clinician and the radiologist before the scan date.

Blood Pressure Considerations With Contrast and Jatenzo

Jatenzo's Effect on Blood Pressure

The FDA label for Jatenzo includes a boxed warning about blood pressure elevation [1]. In clinical trials, mean systolic blood pressure increased by approximately 3 to 5 mmHg from baseline. The label specifically instructs prescribers to monitor blood pressure and to use Jatenzo with caution in patients with pre-existing hypertension or cardiovascular disease [1]. A 2021 meta-analysis of 11 randomized controlled trials (N=1,822) in the Journal of the American Heart Association found that exogenous testosterone raised systolic BP by a pooled mean of 3.2 mmHg (95% CI 1.4 to 5.1, P<0.001) compared to placebo [6].

Contrast Injection and Blood Pressure

Iodinated contrast can cause a transient vasovagal or anaphylactoid reaction that acutely lowers blood pressure, or, less commonly, a hypertensive spike in patients with pheochromocytoma or underlying vascular disease [3]. For most patients on Jatenzo, this dual-direction BP variability is manageable with standard pre-medication and monitoring protocols. Still, the radiologist should know your current systolic BP reading, because facilities typically postpone elective contrast procedures when systolic BP exceeds 180 mmHg [3].

Pre-Procedure BP Threshold

Most radiology departments follow a facility-specific protocol based on ACR guidance. If your systolic BP is controlled below 160 mmHg on or off antihypertensives, the contrast procedure can generally proceed [3]. Jatenzo-associated hypertension that is already managed pharmacologically does not add a separate contraindication to contrast, but the radiologist should document it.

Gadolinium-Based Contrast Agents: Is the Risk Different?

MRI contrast agents (gadolinium-based) carry a separate risk profile from iodinated agents. Gadolinium is eliminated almost entirely by glomerular filtration. In patients with severely reduced kidney function (eGFR <30 mL/min/1.73 m²), gadolinium may accumulate and, historically, has been associated with nephrogenic systemic fibrosis (NSF), though the newer macrocyclic agents (gadobutrol, gadoteridol) carry negligible NSF risk [7]. Testosterone therapy itself does not reduce eGFR in patients with normal baseline renal function [8]. The concern returns to hematocrit: if polycythemia from Jatenzo has compromised renal perfusion over months, eGFR may be lower than expected, elevating gadolinium retention risk.

eGFR Screening Before MRI With Contrast

The ACR recommends eGFR screening before GBCM administration in patients with known or suspected renal disease, diabetes, or age above 60 [3]. Because Jatenzo therapy can raise hematocrit and BP, both of which, if uncontrolled, may silently reduce glomerular filtration over time, an eGFR check before MRI contrast is a reasonable precaution even in younger Jatenzo users who appear otherwise healthy [8].

A Practical Decision Framework for Jatenzo Patients Scheduled for Contrast Imaging

Use this step-by-step checklist in the 2 to 4 weeks before a contrast-enhanced study:

1. Check labs. Order hematocrit (or full CBC), serum creatinine, and calculated eGFR. These results should be no older than 30 days at the time of the procedure.
2. Review hematocrit threshold. Hematocrit at or above 54%: notify both prescriber and radiologist. The radiologist may choose a lower-osmolality contrast agent or increase IV hydration peri-procedure.
3. Measure blood pressure. If systolic BP exceeds 160 mmHg on the day of the scan, most facilities postpone elective contrast studies. Bring your home BP log.
4. Disclose Jatenzo dose and timing. Tell the radiologist your current dose (158 mg, 198 mg, or 237 mg twice daily) and the date of your last hematocrit check.
5. Hydrate. Standard pre-contrast hydration (IV normal saline 1 mL/kg/hr for 3 to 12 hours before and after) reduces CI-AKI risk. Oral hydration (500 to 1000 mL water in the 4 hours before the scan) is appropriate for outpatients without IV access [9].
6. No automatic hold. You do not need to stop Jatenzo before the scan. No pharmacokinetic reason supports a medication hold.
7. Post-scan renal check. If hematocrit was elevated pre-procedure, a serum creatinine 48 to 72 hours after contrast confirms no CI-AKI developed.

The ACR defines CI-AKI as a rise in serum creatinine of 0.5 mg/dL or 25% above baseline within 48 to 72 hours of contrast administration [3].

Jatenzo and Alcohol: What the Label Says

FDA Label Requirement and Alcohol

This question comes up frequently in clinical practice because Jatenzo's absorption depends entirely on dietary fat, and alcohol-containing meals confuse the picture. The FDA label states that Jatenzo must be taken with a meal; the meal should contain at least 20 to 23 g of fat to drive lymphatic absorption [1]. Alcohol itself does not appear on the label as a contraindicated substance, but alcohol is vasodilatory and can transiently lower blood pressure, which may partially offset Jatenzo's pressor effect, or, in some individuals, cause exaggerated BP swings [10].

Alcohol, Blood Pressure, and Contrast Timing

If you are drinking the night before a contrast scan, the concern is not a Jatenzo-alcohol-contrast triad of harm. The concern is dehydration. Alcohol is a diuretic. Even moderate intake (two to three standard drinks) can reduce intravascular volume by several hundred milliliters overnight [10]. Dehydration is one of the three top modifiable risk factors for CI-AKI listed by the ACR [3]. The practical instruction: avoid alcohol for at least 12 hours before any contrast procedure, independent of Jatenzo use.

Chronic Heavy Alcohol Use and Testosterone

Chronic alcohol use (more than 14 standard drinks per week) suppresses the hypothalamic-pituitary-gonadal axis and reduces endogenous testosterone production, as demonstrated in a study of 50 men with alcohol use disorder published in Alcohol and Alcoholism (mean testosterone 8.4 nmol/L vs. 18.2 nmol/L in controls, P<0.001) [11]. Patients on Jatenzo for hypogonadism who drink heavily may require higher doses to maintain target testosterone levels (450 to 1050 ng/dL per the Endocrine Society guideline) [12], and the resulting higher hematocrit exposure worsens contrast-related risk. This is one reason prescribers counsel against heavy alcohol use during TRT.

Iodinated Contrast Agent Selection in Patients on Jatenzo

Not all iodinated contrast agents carry equal nephrotoxicity risk. Iso-osmolar agents (iodixanol, osmolality ~290 mOsm/kg) produce less renal tubular stress than high-osmolality agents (osmolality 1400 to 1800 mOsm/kg) [9]. For Jatenzo users with hematocrit above 50% or eGFR between 30 and 60 mL/min/1.73 m², requesting an iso-osmolar or low-osmolality agent (iopamidol, iohexol) from the radiologist is a reasonable conversation to have. A Cochrane review of 28 trials (N=9,128) found that low-osmolality agents reduced CI-AKI incidence by approximately 50% compared to high-osmolality agents in high-risk patients (RR 0.50, 95% CI 0.36 to 0.68) [9].

N-Acetylcysteine: No Longer Recommended

For years, N-acetylcysteine (NAC) was given before contrast to reduce CI-AKI. The PRESERVE trial (N=4,993) published in the New England Journal of Medicine found that NAC did not reduce the incidence of contrast-associated AKI, death, or dialysis compared to placebo (RR 1.02, 95% CI 0.89 to 1.17) [13]. The ACR no longer recommends routine NAC pre-medication [3]. Mentioning this matters because some Jatenzo users may find older online protocols recommending NAC; those protocols are outdated.

IV Saline vs. Sodium Bicarbonate

The PRESERVE trial also compared IV sodium bicarbonate to IV normal saline for CI-AKI prevention [13]. No significant difference emerged. Normal saline at 1 mL/kg/hr remains the standard peri-procedural hydration strategy for most patients, including those on testosterone replacement [3][13].

Testosterone, Erythrocytosis, and Thrombotic Risk Around Contrast Procedures

Polycythemia from testosterone use raises erythrocyte count, which directly increases blood viscosity and the risk of venous thromboembolism (VTE). Contrast-enhanced procedures, particularly those requiring prolonged immobility (e.g., multi-hour cardiac MRI or PET-CT), create a post-procedural period of relative stasis. A retrospective cohort study in JAMA Internal Medicine (N=39,622) found that exogenous testosterone use was associated with a 63% higher risk of VTE compared to non-users (HR 1.63, 95% CI 1.12 to 2.37) [14]. Patients with hematocrit above 54% on Jatenzo who undergo a lengthy imaging procedure should consider post-procedure ambulation as early as possible and discuss short-term VTE prophylaxis with their clinician if other risk factors (obesity, prior DVT, prolonged immobility) are present.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We suggest checking hematocrit at baseline, 3 to 6 months after starting treatment, and then annually. If hematocrit exceeds 54%, stop therapy until hematocrit decreases to a safe level" [12]. That threshold applies at all times, not only around imaging procedures.

Special Populations: Cardiovascular Disease and Diabetes

Patients with pre-existing cardiovascular disease or type 2 diabetes face a compounded contrast risk that overlaps with testosterone therapy. The FDA label for Jatenzo carries a specific warning for use in men with serious cardiovascular conditions, noting that testosterone may increase the risk of major adverse cardiovascular events [1]. The ACR identifies diabetes and pre-existing cardiovascular disease independently as CI-AKI risk factors [3]. A patient who is diabetic, on Jatenzo, with a hematocrit of 52% and an eGFR of 45 mL/min/1.73 m² sits in a distinctly higher-risk tier, and the ordering clinician should discuss whether the imaging indication is strong enough to justify iodinated contrast versus an unenhanced alternative.

A 2019 study in Diabetes Care (N=5,744) found that eGFR <60 mL/min/1.73 m² combined with diabetes conferred a 3.1-fold higher odds of CI-AKI following coronary angiography compared to patients with normal renal function and no diabetes (OR 3.10, 95% CI 2.11 to 4.55, P<0.001) [15]. Testosterone-driven polycythemia adds a further multiplicative layer of risk in this population.

What to Tell Your Imaging Center

When you check in for a contrast-enhanced scan, give the technologist and radiologist the following specific information:

• Medication name: Jatenzo (oral testosterone undecanoate)
• Current dose: 158 mg, 198 mg, or 237 mg twice daily with meals
• Most recent hematocrit result and date
• Most recent eGFR and creatinine result and date
• Current systolic blood pressure
• Any antihypertensive medications taken concurrently
• History of prior contrast reactions, if any

This list takes under two minutes to communicate and gives the radiology team everything needed to choose the safest contrast agent, dose, and hydration strategy for your individual risk profile.